We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

49 hedge funds and large institutions have $10.4M invested in Cue Biopharma in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more call options, than puts

Call options by funds: $20K | Put options by funds: $6K

0.02% less ownership

Funds ownership: 0.62% → 0.6% (-0.02%)

9% less funds holding

Funds holding: 54 → 49 (-5)

19% less capital invested

Capital invested by funds: $12.8M → $10.4M (-$2.44M)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
49
Holders Change
-5
Holders Change %
-9.26%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
10
Closed
12
Calls
$20K
Puts
$6K
Net Calls
+$14K
Net Calls Change
-$25K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$321K
2
CPIG
Chicago Partners Investment Group
Illinois
+$112K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$77.5K
4
Renaissance Technologies
Renaissance Technologies
New York
+$45.8K
5
Squarepoint
Squarepoint
New York
+$18.7K

Top Sellers

Rank Fund Capital Flow
1
GLA
Good Life Advisors
Pennsylvania
-$436K
2
SPC
Sigma Planning Corp
Michigan
-$150K
3
Millennium Management
Millennium Management
New York
-$75.5K
4
Jane Street
Jane Street
New York
-$69.5K
5
HF
HRT Financial
New York
-$53K
Name Holding Trade Value Shares
Change 		Change in
Stake
SG
26
StoneX Group
New York
$12.8K +$17.4K +469 New
Group One Trading
27
Group One Trading
Illinois
$12.4K +$16.8K +452 New
SWM
28
SeaCrest Wealth Management
New York
$11.8K – – –
TSS
29
Two Sigma Securities
New York
$9.46K +$12.8K +346 New
Northwestern Mutual Wealth Management
30
Northwestern Mutual Wealth Management
Wisconsin
$9.11K +$9.28K +250 +301%
BPA
31
Beacon Pointe Advisors
California
$9.11K – – –
Barclays
32
Barclays
United Kingdom
$5.49K – – –
GG
33
Gleason Group
Kentucky
$5.47K – – –
TRCT
34
Tower Research Capital (TRC)
New York
$3.53K -$8.24K -222 -63%
NFSG
35
Newbridge Financial Services Group
Florida
$3.19K +$631 +17 +17%
NA
36
NewEdge Advisors
Louisiana
$2.32K – – –
Simplex Trading
37
Simplex Trading
Illinois
$2K -$5.57K -150 -65%
GSWM
38
Golden State Wealth Management
California
$1.82K – – –
T
39
Tidemark
California
$1.37K +$1.86K +50 New
JP Morgan Chase
40
JP Morgan Chase
New York
$958 – – –
PWA
41
Physician Wealth Advisors
Utah
$917 – – –
MG
42
Mather Group
Illinois
$911 +$1.23K +33 New
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$651 -$149 -4 -14%
Osaic Holdings
44
Osaic Holdings
Arizona
$618 +$371 +10 +77%
MCM
45
MAI Capital Management
Ohio
$319 – – –
SS
46
Sunbelt Securities
Texas
$216 – – –
AAG
47
Armstrong Advisory Group
Massachusetts
$131 – – –
IA
48
IFP Advisors
Florida
$91 – – –
SFGP
49
Stonebridge Financial Group (Pennsylvania)
Pennsylvania
$56 – – –
GLA
50
Good Life Advisors
Pennsylvania
– -$436K -13,333 Closed
1
2
3

CUE Hedge Fund Activity: Q1 2025 in Review

49 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2025, worth a combined $10.4M — down 19% from $12.8M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CUE and 7 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $321K. The largest seller was Good Life Advisors, exiting entirely with an estimated $436K sold.

  • 49 institutional investors held Cue Biopharma (CUE) as of Q1 2025, down from 54 in Q4 2024.
  • Funds reported $10.4M of Cue Biopharma stock for Q1 2025, down 19% quarter-over-quarter.
  • 7 funds opened new Cue Biopharma positions in Q1 2025 and 12 closed out, a net change of -5 holders.
  • The largest Cue Biopharma buyer in Q1 2025 was Vanguard Group, an estimated $321K added.
  • The largest Cue Biopharma seller in Q1 2025 was Good Life Advisors, an estimated $436K sold.

Based on aggregated 13F filings for Q1 2025.